Wikinski Silvia
Médica Psiquiatra, Doctora de la Universidad de Buenos Aires, Miembro de la Carrera de Investigador Científico (ININFA-CONICET).
Vertex. 2008 Jul-Aug;19(80):196-200.
This work postulates the thesis that the development of the contemporary psychopharmacology, which began with the chemical changes imposed to molecules with antihistaminergic properties, modelled the current ethiopatogenic theories of mental diseases. The development of chlorpromazine and imipramine was coincident with the beginning of the research about neurotransmission. This coincidence contributed for the construction of the dopaminergic theory of schizophrenia and in the monoaminergic theory of depression. Limitations of the effectivity of current drugs, as observed in the trials CATIE and STAR-D may justify a change of perspective in the search for new molecular targets for the treatment of both diseases. Historical data are provided to illustrate the above mentioned thesis, in the perspective of two epistemological concepts: the context of discovery proposed by Hans Reichenbach and the epistemological obstacle, proposed by Gaston Bachelard.
当代精神药理学的发展始于对具有抗组胺特性的分子进行化学改变，它塑造了当前精神疾病的病因致病理论。氯丙嗪和丙咪嗪的发展与神经传递研究的开端是同时期的。这种巧合促成了精神分裂症的多巴胺能理论和抑郁症的单胺能理论的构建。正如在CATIE和STAR-D试验中所观察到的，当前药物有效性的局限性可能为寻找这两种疾病治疗的新分子靶点时改变视角提供了依据。从两个认识论概念的角度提供了历史数据来说明上述论点：汉斯·赖兴巴赫提出的发现语境，以及加斯东·巴什拉提出的认识论障碍。
